Cannabics Pharmaceuticals Inc
CNBX Pharmaceuticals Inc., a clinical-stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug… Read more
Cannabics Pharmaceuticals Inc - Asset Resilience Ratio
Cannabics Pharmaceuticals Inc (CNBX) has an Asset Resilience Ratio of 31.77% as of November 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2020)
This chart shows how Cannabics Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Cannabics Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $539.61K | 31.77% |
| Total Liquid Assets | $539.61K | 31.77% |
Asset Resilience Insights
- Very High Liquidity: Cannabics Pharmaceuticals Inc maintains exceptional liquid asset reserves at 31.77% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Cannabics Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Cannabics Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Cannabics Pharmaceuticals Inc (2017–2020)
The table below shows the annual Asset Resilience Ratio data for Cannabics Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-08-31 | 0.00% | $0.00 | $2.22 Million | -- |
| 2019-08-31 | 21.45% | $3.26 Million | $15.18 Million | -- |
| 2018-08-31 | 0.00% | $0.00 | $3.18 Million | -- |
| 2017-08-31 | 0.00% | $0.00 | $3.64 Million | -- |